Official websites use .gov
Secure .gov websites use HTTPS
« Previous
Next »
Titles
- Medicaid's most costly outpatient drugs2
- A comparison of brand-name drug prices among selected federal programs1
- Assessing user fees under the Prescription Drug User Fee Amendments of 20171
- Brand name drug prices increase more than twice as fast as inflation in 20181
- Brand name prescription drug prices increase four times faster than inflation in 20171
- Changes in the list prices of prescription drugs, 2017-20231
- Competition in prescription drug markets, 2017-20221
- Cost savings1
- Drug price increases that exceed inflation are costing Medicare Part D billions1
- Filling the Medicaid gap with a public option1
- Getting to lower prescription drug prices: the key drivers of costs and what policymakers can do to address them1
- Getting to the root of high prescription drug prices: drivers and potential solutions1
- How does the Trump Administration drug pricing blueprint affect Medicaid?1
- Medicare Part D1
- Medicare Part D: CMS should monitor effects of rebates on drug coverage and spending : testimony before the Subcommittee on Health, Committee on Energy and Commerce, House of Representatives1
- Prescription drug spending by Medicare beneficiaries in institutional and residential settings, 1998-20011
- Prescription drugs: U.S. prices for selected brand drugs were higher on average than prices in Australia, Canada, and France : report to the Chairman, Committee on the Budget, U.S. Senate1
- Prescription drugs: spending, use, and prices1
- Price decreases for widely used generic drugs slow in 2017 after two years of substantial price drops1
- Price increases for prescription drugs: 2016-20221